US 12,109,251 B2
Satiation peptide administration
Sergei Zolotukhin, Gainesville, FL (US); and Andres Acosta, Rochester, MN (US)
Assigned to University of Florida Research Foundation, Incorporated, Gainesville, FL (US)
Filed by University of Florida Research Foundation, Incorporated, Gainesville, FL (US)
Filed on Jul. 2, 2021, as Appl. No. 17/366,825.
Application 15/271,369 is a division of application No. 13/145,660, granted, now 9,492,505, previously published as PCT/US2010/021677, filed on Jan. 21, 2010.
Application 17/366,825 is a continuation of application No. 16/562,382, filed on Sep. 5, 2019, granted, now 11,103,556.
Application 16/562,382 is a continuation of application No. 15/271,369, filed on Sep. 21, 2016, abandoned.
Claims priority of provisional application 61/146,287, filed on Jan. 21, 2009.
Prior Publication US 2021/0401942 A1, Dec. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/22 (2006.01); A61K 9/00 (2006.01); A61K 9/68 (2006.01); A61K 48/00 (2006.01); C07K 14/575 (2006.01)
CPC A61K 38/22 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0056 (2013.01); A61K 9/0058 (2013.01); A61K 9/006 (2013.01); A61K 48/005 (2013.01); A61K 48/0075 (2013.01); C07K 14/575 (2013.01); C12N 2799/025 (2013.01)] 9 Claims
 
7. A dissolvable solid or semi-solid pharmaceutical composition comprising a satiation gut peptide and a pharmaceutically acceptable carrier in a unit dosage form, wherein the satiation gut peptide is selected from the group consisting of PYY, Glucagon-like Peptide-1, Oxyntomodulin, and Cholecystokinin,
wherein the unit dosage form provides no substantial change to the concentration of the satiation gut peptide in the plasma after the delivery, wherein the unit dosage form is configured to contact the tongue of the subject for at least 5 seconds.